Bioxyne Ltd - Company Profile
Powered by 
All the data and insights you need on Bioxyne Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Bioxyne Ltd Strategy Report
- Understand Bioxyne Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Bioxyne Ltd (Bioxyne) is a biotechnology company that develops, manufactures, markets, and commercializes healthcare products in the areas of immune health and immunotherapeutic. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as a foodstuffs, dietary supplements, and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. Bioxyne is headquartered in Sydney, New South Wales, Australia
Headquarters
Australia
Address
Se 506 L 5, 50 Clarence Street, Sydney, New South Wales, 2000
Website
www.bioxyne.com
Telephone
61 2 90788180
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BXN (ASX)
Revenue (2023)
$3.6M
-78%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
0.3%
(2023 vs 2022)
Market Cap*
$10.7M
Net Profit Margin (2023)
XYZ
64.3%
(2023 vs 2022)
* As of and is in US$
Bioxyne Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Consumer Food Supplements: | Col-ME |
| ProTract | Progastrim |
| Col-ME | ProTract |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In July, the company acquired Breathe Life Sciences Pty Ltd. |
| 2016 | Contracts/Agreements | In December, the company launched its two new brand probiotic product, Progastrim and proTract; for gut and immune health and atopic dermatitis (eczema) respectively, in Australia. |
| 2016 | Contracts/Agreements | In June, Bioxyne signed an agreement with Datapharm to carry out a clinical trial, supporting the launch and marketing of Progastrim and proTract. |
Competitor Comparison
| Key Parameters | Bioxyne Ltd | Probiotec Ltd | BLIS Technologies Ltd | Amplia Therapeutics Ltd | BioCeuticals Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | New Zealand | Australia | Australia |
| City | Sydney | Melbourne | Dunedin | Melbourne | Alexandria |
| State/Province | New South Wales | Victoria | Otago | Victoria | New South Wales |
| No. of Employees | 16 | 111 | 10 | 1 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| N H Chua | Chief Executive Officer; Director; Managing Director | Executive Board | 2017 | - |
| Guy Adrian Robertson | Chief Financial Officer; Director; Secretary | Senior Management | 2022 | - |
| Anthony Peng Ho | Chairman | Non Executive Board | 2012 | - |
| Samuel Watson | Chief Executive Officer; Managing Director; Director | Senior Management | - | - |
| Jason Hine | Chief Operating Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer